About this Research Topic
Cardiovascular disease (CVD) is the leading cause of death globally, with WHO estimates stating it represents 32% of deaths worldwide. This disease is a group of disorders of the heart and vasculature. There are many risk factors for developing a cardiovascular disease, including unhealthy diet, lack of mobility, alcohol, pollution and tobacco smoking.
Further to this, drug-induced cardiotoxicity is of critical interest to the pharmaceutical and medicinal field, as this endpoint is a leading cause of adverse events in the clinic and subsequent withdrawal of medicines from the market (some estimates suggest 10% of drugs have been removed for this reason). Although these drugs are currently tested in animals, numerous different drugs have been shown to induce a wide variety of cardiotoxic symptoms (including electrophysiological and structural defects). This highlights that the existing assessment strategy is not sufficient for this endpoint.
Clearly, there is a need for human physiologically relevant methods to assess these adverse outcomes to gain mechanistic understanding of cardiovascular disease processes, de-risk drug development and ultimately form interventions to prevent them from occurring.
This Research Topic looks to showcase the emerging new approach methodologies being developed to model cardiovascular disease and/or cardiotoxicity, without the reliance on animal testing. With advances in science and technology there has been a rapid emergence of new techniques available to assess these endpoints, including high throughput Human Induced pluripotent stem cell derived cardiomyocytes, Co-Culture assays, Organ on a Chip and Multi-organ on a chip assays. It is important to note that New Approach Methodologies which use animal-derived products are not truly replaceable, therefore we should focus on New Approach Methodologies which do not use animal-deprived products.
This Research Topic is looking to receive publications which focus on techniques which are either completely animal and/or animal-product free. We welcome themes including (but not limited to):
• Adverse outcome pathways assessing aspects of CVD or Cardiotoxicity
• Techniques utilising in vitro or in silico analyses, assessing drugs, chemicals or complex mixtures in cardiovascular endpoints
• Integrated testing strategies utilising NAMs
• Case studies where NAMs data has been used successfully in regulatory submissions
Authors are invited to submit original research articles, reviews, and perspectives that address the theme of this Research Topic.
Further to this, drug-induced cardiotoxicity is of critical interest to the pharmaceutical and medicinal field, as this endpoint is a leading cause of adverse events in the clinic and subsequent withdrawal of medicines from the market (some estimates suggest 10% of drugs have been removed for this reason). Although these drugs are currently tested in animals, numerous different drugs have been shown to induce a wide variety of cardiotoxic symptoms (including electrophysiological and structural defects). This highlights that the existing assessment strategy is not sufficient for this endpoint.
Clearly, there is a need for human physiologically relevant methods to assess these adverse outcomes to gain mechanistic understanding of cardiovascular disease processes, de-risk drug development and ultimately form interventions to prevent them from occurring.
This Research Topic looks to showcase the emerging new approach methodologies being developed to model cardiovascular disease and/or cardiotoxicity, without the reliance on animal testing. With advances in science and technology there has been a rapid emergence of new techniques available to assess these endpoints, including high throughput Human Induced pluripotent stem cell derived cardiomyocytes, Co-Culture assays, Organ on a Chip and Multi-organ on a chip assays. It is important to note that New Approach Methodologies which use animal-derived products are not truly replaceable, therefore we should focus on New Approach Methodologies which do not use animal-deprived products.
This Research Topic is looking to receive publications which focus on techniques which are either completely animal and/or animal-product free. We welcome themes including (but not limited to):
• Adverse outcome pathways assessing aspects of CVD or Cardiotoxicity
• Techniques utilising in vitro or in silico analyses, assessing drugs, chemicals or complex mixtures in cardiovascular endpoints
• Integrated testing strategies utilising NAMs
• Case studies where NAMs data has been used successfully in regulatory submissions
Authors are invited to submit original research articles, reviews, and perspectives that address the theme of this Research Topic.
Keywords: Cardiovascular, Cardiotoxicity, NAMs, TT21C, In Vitro, In Silico, IATA
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
